D. Boral Capital Reaffirms “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $46.00 price objective on the biotechnology company’s stock. D. Boral Capital’s price target indicates a potential upside of 443.09% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, January 28th.

Anavex Life Sciences Stock Down 2.6 %

Shares of AVXL opened at $8.47 on Wednesday. Anavex Life Sciences has a 12-month low of $3.25 and a 12-month high of $14.44. The business’s fifty day moving average is $9.94 and its 200 day moving average is $7.70. The stock has a market cap of $718.43 million, a P/E ratio of -16.29 and a beta of 0.69.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. On average, analysts expect that Anavex Life Sciences will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Anavex Life Sciences

Large investors have recently bought and sold shares of the stock. Barclays PLC lifted its stake in Anavex Life Sciences by 70.4% during the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 64,101 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 14,892 shares in the last quarter. Franklin Resources Inc. lifted its stake in Anavex Life Sciences by 6.7% during the 3rd quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company’s stock valued at $317,000 after acquiring an additional 3,674 shares in the last quarter. Nwam LLC bought a new position in Anavex Life Sciences during the 3rd quarter valued at $5,172,000. Finally, Geode Capital Management LLC lifted its stake in Anavex Life Sciences by 2.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock valued at $10,699,000 after acquiring an additional 51,946 shares in the last quarter. 31.55% of the stock is currently owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.